RCUS - Arcus Biosciences, Inc.
NEXT EARNINGS:
Feb 25, 2026
(in 1 day)
EPS Est: $-1.11
|
Rev Est: $24.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.00
DETAILS
HIGH:
$35.00
LOW:
$20.00
MEDIAN:
$29.00
CONSENSUS:
$28.00
UPSIDE:
38.68%
Market Cap:
2.03B
Volume:
1,449,759
Avg Volume:
1,602,770
52 Week Range:
6.5-26.4
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.84
Last Dividend:
$N/A
Exchange:
NYSE
Country:
US
Employees:
627
IPO Date:
2018-03-15
EPS (TTM):
-3.14
P/E Ratio:
-4.74
Revenue (TTM):
258.00M
Total Assets:
1.15B
Total Debt:
60.00M
Cash & Equiv:
150.00M
Rev Growth (5Y):
76.6%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-30.2%
Debt/Equity:
0.12
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-28 | $-1.27 | $-1.33 | +4.5% | $26.0M | $24.9M | +4.3% |
| 2025-08-06 | $-0.08 | $-1.14 | +93.4% | $160.0M | $32.5M | +392.6% |
| 2025-05-06 | $-1.14 | $-1.02 | -11.8% | $28.0M | $37.4M | -25.0% |
| 2025-02-25 | $-1.03 | $-1.17 | +12.0% | $26.0M | $29.4M | -11.5% |
| 2024-11-06 | $-1.00 | $-1.07 | +6.5% | $48.0M | $32.1M | +49.7% |
| 2024-08-08 | $-1.02 | $-1.02 | 0.0% | $39.0M | $25.6M | +52.3% |
| 2024-05-08 | $-0.05 | $-0.97 | +94.8% | $145.0M | $35.6M | +307.8% |
| 2024-02-21 | $-1.08 | $-1.09 | +0.9% | $31.0M | $28.2M | +10.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 258.00M | 117.00M | 112.00M | 383.00M | 78.00M | 15.00M | 8.35M | 1.41M | 0 |
| Net Income | (283.00M) | (307.00M) | (267.00M) | 53.00M | (123.00M) | (84.71M) | (49.59M) | (53.08M) | (17.97M) |
| EPS | -3.14 | -4.15 | -3.71 | 0.76 | -2.13 | -1.73 | -1.43 | -2.16 | -0.73 |
| Total Assets | 1.15B | 1.09B | 1.34B | 1.59B | 772.29M | 203.11M | 274.93M | 190.49M | 109.70M |
| Total Debt | 60.00M | 11.00M | 120.00M | 121.99M | 18.11M | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 150.00M | 127.00M | 206.00M | 147.91M | 173.41M | 57.94M | 71.06M | 98.43M | 65.16M |
| Operating Cash Flow | (170.00M) | (306.00M) | 438.00M | (256.17M) | 111.17M | (73.46M) | (43.00M) | (25.06M) | (12.94M) |
| Free Cash Flow | (176.00M) | (330.00M) | 432.00M | (282.25M) | 108.11M | (75.39M) | (46.74M) | (30.57M) | (17.04M) |
| FCF per Share | -1.95 | -4.46 | 6.00 | -4.07 | 1.97 | -1.72 | -1.35 | -1.25 | -0.69 |
| Book Value | 485.00M | 462.00M | 657.00M | 841.45M | 502.30M | 163.84M | 234.94M | 153.87M | 99.46M |
| Cash & ST Investments | 978.00M | 759.00M | 1.01B | 499.31M | 728.65M | 188.27M | 256.54M | 175.70M | 98.90M |
| ROC Equity | -0.58 | -0.66 | -0.41 | 0.06 | -0.24 | -0.52 | -0.21 | -0.34 | -0.18 |